This potential biological advantage underscores the role of ADAM33 as a modifier gene influencing disease phenotype and therapeutic responsiveness in CF, reinforcing the value of integrating genetic profiling with pulmonary functional assessment for personalized management and risk stratification in CF. This evidence concerns the gene ADAM33 and cystic fibrosis.